Literature DB >> 12077071

Sensation and gas dynamics in functional gastrointestinal disorders.

J-R Malagelada1.   

Abstract

Our current knowledge of motor and sensory functions in the human gut is critically reviewed, showing how the two may interact to produce symptoms in patients with functional gastrointestinal disorders. A local stimulus is necessary to activate the pathogenetic symptom generation process, and in many patients abnormal pooling of gas at various or extensive sites in the bowel and focal gut distension may provide the local stimulus, compounded by spatial summation phenomena and conscious visceral hypersensitivity. The interplay of these mechanisms results in the clinical expression of symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077071      PMCID: PMC1867726          DOI: 10.1136/gut.51.suppl_1.i72

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation.

Authors:  J Serra; F Azpiroz; J R Malagelada
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-07       Impact factor: 4.052

Review 2.  Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management.

Authors:  F De Ponti; J R Malagelada
Journal:  Pharmacol Ther       Date:  1998-10       Impact factor: 12.310

3.  Modulation of gut perception in humans by spatial summation phenomena.

Authors:  J Serra; F Azpiroz; J R Malagelada
Journal:  J Physiol       Date:  1998-01-15       Impact factor: 5.182

4.  Modification of small bowel mechanosensitivity by intestinal fat.

Authors:  A M Accarino; F Azpiroz; J R Malagelada
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  Quantificantion of gastric solid-liquid discrimination during digestion of ordinary meals.

Authors:  J R Malagelada
Journal:  Gastroenterology       Date:  1977-06       Impact factor: 22.682

6.  Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome.

Authors:  J Serra; F Azpiroz; J R Malagelada
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

7.  Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.

Authors:  M Camilleri; E A Mayer; D A Drossman; A Heath; G E Dukes; D McSorley; S Kong; A W Mangel; A R Northcutt
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

8.  The role of psychological and biological factors in postinfective gut dysfunction.

Authors:  K A Gwee; Y L Leong; C Graham; M W McKendrick; S M Collins; S J Walters; J E Underwood; N W Read
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

9.  Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population.

Authors:  N J Talley; P Boyce; M Jones
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

10.  Quantification of the fate of dietary fiber in humans by a newly developed radiolabeled fiber marker.

Authors:  P W Carryer; M I Brown; J R Malagelada; G L Carlson; J T McCall
Journal:  Gastroenterology       Date:  1982-06       Impact factor: 22.682

View more
  3 in total

1.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Computed tomography assessment of intestinal gas volumes in functional gastrointestinal disorders.

Authors:  Sebastian R Mc Williams; Patrick D Mc Laughlin; Owen J O'Connor; Alan N Desmond; Aine Ní Laoíre; Fergus Shanahan; Eamonn Mm Quigley; Michael M Maher
Journal:  J Neurogastroenterol Motil       Date:  2012-10-09       Impact factor: 4.924

3.  Pimpinella anisum in the treatment of functional dyspepsia: A double-blind, randomized clinical trial.

Authors:  S Ashraffodin Ghoshegir; Mohammad Mazaheri; Alireza Ghannadi; Awat Feizi; Mahmoud Babaeian; Maryam Tanhaee; Mehrdad Karimi; Peyman Adibi
Journal:  J Res Med Sci       Date:  2015-01       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.